High-Throughput miRNA Screening for Anti-HIV Pathway Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for identifying and utilizing anti-HIV microRNAs and pharmaceutical compounds that effectively modulate HIV infection, as they fail to comprehensively address the complex interactions between host miRNAs and HIV, particularly in targeting specific pathways and nucleic acids/polypeptides involved in HIV replication and immune response.
Innovation Solution
A high-throughput screening method involving reporter cells transfected with miRNAs and treated with pharmaceutical compounds to identify miRNAs and compounds that modulate HIV infection by targeting specific cellular pathways, polynucleotides, and polypeptides, including the use of miRNA mimics and inhibitors to either inhibit or enhance HIV replication and induce apoptosis in infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-throughput screening methods are used to identify anti-HIV miRNAs and pharmaceutical compounds, then the ability to comprehensively identify miRNAs and compounds that modulate HIV infection is improved, but the complexity of the screening process and analysis increases
Solution Approach 1:
The screening process is divided into distinct modules: (1) transfection of reporter cells with individual miRNAs from the panel, (2) infection with HIV, (3) high-throughput screening to identify modulating miRNAs, and (4) identification of targeted pathways and polypeptides. This segmentation allows systematic identification while managing complexity through structured workflow
Solution Approach 2:
Reporter cells serve as an intermediary system that translates complex miRNA-HIV interactions into measurable signals. These reporter cells contain HIV LTR promoter-driven reporters that respond to miRNA modulation, enabling high-throughput detection without directly analyzing complex viral-host interactions
2Loss of information
If reporter cells are transfected with a panel of miRNAs and screened to identify anti-HIV miRNAs, then the identification of specific pathways and polypeptides targeted by miRNAs is improved, but the time and resources required for comprehensive screening increase
Solution Approach 1:
Reporter cells are pre-engineered with HIV LTR promoter-driven reporters before screening begins. This preliminary preparation allows direct measurement of miRNA effects on HIV replication pathways without time-consuming setup during the actual screening process
Solution Approach 2:
The method measures changes in reporter signal intensity as a parameter to quantify miRNA modulation of HIV infection. By converting complex biological interactions into quantifiable signal changes, the system enables rapid high-throughput screening while capturing comprehensive pathway information
Data Source
AI summary
The present invention relates to methods for the identification of anti-HIV miRNAs and anti-HIV pharmaceutical compounds using high-throughput screening methods, comprising: transfecting reporter cells with a panel of miRNAs, infecting the reporter cells with HIV, screening the cells to identify miRNAs that modulate HIV infection and identifying the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs. The invention further provides for the identification and screening of anti-HIV pharmaceutical compounds having known activity against the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs for efficacy in the treatment of HIV. The invention also provides for the use of miRNA mimics, miRNA inhibitors and pharmaceutical compounds (including oncology drugs and kinase inhibitors) in the treatment and/or prevention of HIV infection.